Last updated: February 27, 2026
What is the excipient composition of RECARBRIO?
RECARBRIO (imipenem, cilastatin, and relebactam) is an intravenous broad-spectrum antibiotic. Its formulation primarily includes the active pharmaceutical ingredients (APIs) and excipients to ensure stability, bioavailability, and compatibility. The formulation typically comprises:
- Active Ingredients: Imipenem, cilastatin, relebactam
- Excipients:
- Sodium bicarbonate (buffering agent)
- Sodium citrate (buffer)
- Zinc sulfate (stabilizer in some formulations)
- Surfactants like polysorbate 80 (stabilizer)
- Preservatives such as sodium chloride or other compatible isotonic agents
- Water for injections (solvent)
Exact excipient composition varies based on the manufacturing process and regional regulatory requirements. The formulation ensures stability in solution, prevents precipitation, and reduces degradation.
How does excipient selection influence RECARBRIO's stability and shelf life?
Excipients play a crucial role in maintaining the therapeutic stability of RECARBRIO, especially considering its nature as an IV formulation. Critical factors include:
- Buffering agents, like sodium citrate and bicarbonate, maintain pH stability around 6.5-7.4, reducing API degradation.
- Surfactants like polysorbate 80 prevent aggregation and surface adsorption, ensuring uniform dosing.
- Preservatives inhibit microbial growth during manufacturing and storage.
- Stabilizers such as zinc sulfate may prevent metal-catalyzed hydrolysis.
Excipients contribute directly to a shelf life typically ranging from 2-3 years under proper storage conditions (2-8°C). Formulation stability affects commercial distribution, especially in regions with less robust cold chain logistics.
What are the current regulatory considerations for excipients in RECARBRIO?
Regulatory filings, such as the FDA's New Drug Application (NDA) and EMA's Marketing Authorization Application (MAA), specify excipients approved for use. For RECARBRIO:
- The excipient list must meet USP, EP, or JP monographs where applicable.
- Any new excipients or uses require supplementary data demonstrating safety and compatibility.
- Excipients must be consistent across manufacturing batches to ensure batch-to-batch uniformity.
Recent regulatory updates emphasize tamper-evident packaging and compatibility testing for excipients, especially surfactants that may cause hypersensitivity in some patients.
What are the commercial opportunities linked to excipient innovations for RECARBRIO?
Advancements in excipient technology can create multiple commercial opportunities:
1. Improved Stability Profiles
Developing novel stabilizers or buffering systems can extend shelf life or simplify storage conditions. For example, replacing cold chain-dependent excipients with heat-stable alternatives opens access to remote markets.
2. Enhanced Bioavailability
Use of excipients that optimize dissolution and absorption, such as tailored surfactants, can improve clinical efficacy, allowing for potential dosage reductions and cost savings.
3. Reduced Manufacturing Costs
Innovations that simplify formulation or reduce the quantity of excipients needed decrease production expenses, increasing profit margins.
4. Compatibility with Autoinjectors and Lyophilized Forms
Designing excipients compatible with innovative delivery formats broadens application, such as pre-filled syringes or freeze-dried formulations, expanding market reach.
5. Regulatory Exclusivities
Patents on specific excipient formulations or stabilization methods can provide extended market exclusivity, reducing generic competition.
6. Sustainability Initiatives
Replacing excipients with environmentally friendly or plant-derived alternatives aligns with global trends, attracting environmentally conscious healthcare providers.
Summary of potential innovation pathways:
| Opportunity |
Description |
Impact |
| Stability enhancement |
Use of novel excipients for extended shelf life |
Broaden geographic distribution |
| Bioavailability optimization |
Formulation with absorption-enhancing excipients |
Reduce dosing and improve efficacy |
| Cost reduction |
Simplify excipient composition |
Improve margins |
| Delivery method compatibility |
Excipient compatibility with novel delivery devices |
Expand product applications |
| Eco-friendly excipients |
Use of biodegradable or sustainably sourced excipients |
Meet environmental standards, marketability |
Competitive landscape and market trends
- Leading competitors include Zerbaxa (ceftolozane/tazobactam) and Vabomere (meropenem/vaborbactam), with focus on formulations and excipients that improve stability and delivery.
- The global antibiotic excipients market is projected to reach $1.2 billion by 2027, growing at a CAGR of 6.3% (Future Market Insights, 2022).
- Innovations in excipient technology, including nanotechnology-based stabilizers and moisture barriers, influence R&D directions.
Regulatory and market risks
- Stringent regulations concerning excipient safety and compatibility.
- Potential for supply chain disruptions of key excipients.
- Patent cliffs for existing formulations may prompt formulation redesign to incorporate new excipients.
Key Takeaways
- Excipient composition in RECARBRIO is critical for stability, bioavailability, and regulatory compliance.
- Innovation in excipients offers opportunities for extending shelf life, reducing costs, and expanding applications.
- Regulatory frameworks favor transparency and safety in excipient use, influencing formulation strategies.
- Market growth in antibiotic excipients supports R&D investments in stabilization and delivery technologies.
- Strategic development of excipients provides a pathway to competitive differentiation and regulatory exclusivity.
FAQs
-
What excipients are most commonly used in IV antibiotics like RECARBRIO?
Buffering agents (sodium citrate, bicarbonate), surfactants (polysorbate 80), stabilizers (zinc sulfate), and isotonic agents (sodium chloride) are common.
-
Can excipient modifications improve RECARBRIO's stability outside cold chain conditions?
Yes, novel excipients can enhance thermal stability, permitting storage at room temperature or elevated temperatures, broadening distribution.
-
What regulatory challenges exist for introducing new excipients in RECARBRIO?
Demonstrating safety, compatibility, and efficacy of new excipients; meeting USP/EP/JP standards; gaining approval documentation.
-
Are there opportunities for patent protection related to excipients in RECARBRIO?
Yes, new formulations or stabilization methods involving unique excipients can be patentable, providing market exclusivity.
-
How does excipient choice impact the commercialization of RECARBRIO in emerging markets?
Excipients that allow for simplified storage, lower costs, and compatibility with local manufacturing infrastructure enhance market penetration.
References
[1] Future Market Insights. (2022). Antibiotic excipients market forecast.
[2] U.S. Food and Drug Administration. (2021). Guidance for industry: Excipient safety and application standards.
[3] European Medicines Agency. (2020). Guidelines on excipient use in medicinal products.
